Chembio Diagnostics

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Hauppauge, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Aptiv

BREA, Calif. , Oct. 17, 2023 /PRNewswire/ -- Life Science Outsourcing, Inc. ("LSO"), a premier contract manufacturer and value-added service provider for the medical device and life science sectors, announces the appointment of Neil A.

Life Science Outsourcing, Inc. Welcomes Neil A. Goldman as Chief Financial Officer

Chembio Diagnostics, Inc. becomes the first North American structure  controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has completed its acquisition of Chembio Diagnostics, Inc. (“Chembio”), a leading point-of-care diagnostics company focused on infectious diseases. Chembio is now part of Biosynex Group.

Biosynex Completes Acquisition of Chembio Diagnostics, Inc.

MILWAUKEE , April 20, 2023 /PRNewswire/ -- Ademi LLP is investigating Chembio (NASDAQ: CEMI) for possible breaches of fiduciary duty and other violations of law in its transaction with Biosynex.  Click here to learn how to join the action https://www.ademilaw.com/case/chembio-diagnostics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Chembio Diagnostics, Inc. has obtained a Fair Price in its transaction with Biosynex

Failure to tender shares could result in the termination of the proposed merger between Chembio and Biosynex Failure to tender shares could result in the termination of the proposed merger between Chembio and Biosynex

Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023

STRASBOURG, France, April 13, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the “Shares”) of Chembio Diagnostics, Inc. (Nasdaq: CEMI) (“Chembio”) at a price of $0.45 per Share, net to the seller in cash, without interest and subject to any required tax withholding, until 6:00 p.m., New York City time on April 26, 2023, unless further extended. The tender offer was previously scheduled to expire at 6:00 p.m., New York City time, on April 12, 2023. All other terms and conditions of the tender offer remain unchanged.

Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.

MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA.

Chembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023

Bright Green Corp

Healthcare Triangle

Hepion Pharmaceuticals Inc

Hillstream Biopharma

Magenta Therapeutics Inc

Sigilon Therapeutics

Spectrum Pharma

The healthcare sector has more high return generating companies than many other sectors.

10 Best-Performing Penny Stocks in the Health Care Sector

Reminder to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023 Reminder to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023

Chembio's CEO Letter to Stockholders

MEDFORD, N.Y., March 21, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA.

Chembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023

MEDFORD, N.Y., March 15, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA.

Chembio Announces Letter to Stockholders Regarding Tender Offer

MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt of a Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the DPP HIV-Syphilis System.

Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System

Wilmington, Delaware--(Newsfile Corp. - February 2, 2023) - Rigrodsky Law, P.A. is investigating Chembio Diagnostics, Inc. ("Chembio") (NASDAQ: CEMI) regarding possible breaches of fiduciary duties and other violations of law related to Chembio's agreement to be acquired by Biosynex SA. Under the terms of the agreement, Chembio's shareholders will receive $0.45 per share in cash.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-chembio-diagnostics-inc.To contact Seth D. Rigrodsky or Gina M.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Chembio Diagnostics, Inc. Buyout

NEW YORK , Feb. 1, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Chembio Diagnostics, Inc. (NASDAQ: CEMI), relating to its proposed sale to Biosynex SA. Under the terms of the agreement, CEMI shareholders are expected to receive $0.45 in cash per share they own.

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Chembio Diagnostics, Inc. - CEMI

NEW YORK--( BUSINESS WIRE )--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chembio Diagnostics, Inc. (NASDAQ: CEMI) to Biosynex SA for $0.45 per share is fair to Chembio shareholders.

CEMI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chembio Diagnostics, Inc. Is Fair to Shareholders

Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers

Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement

HAUPPAUGE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission to the U.S. Food and Drug Administration (FDA) for a Clinical Laboratory Improvement Amendments (CLIA) waiver for the DPP HIV-Syphilis System.

Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System

Chembio Diagnostics, Inc. (NASDAQ:CEMI ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Rick Eberly - President & Chief Executive Officer Larry Steenvoorden - Executive Vice President & Chief Financial Officer Conference Call Participants Per Ostlund - Craig-Hallum Operator Good afternoon, ladies and gentlemen, and welcome to the Chembio Diagnostics Third Quarter 2022 Earnings Conference Call and Webcast. At this time, all participants have been placed in a listen-only mode and the floor will be open for questions after the presentation.

Chembio Diagnostics, Inc. (CEMI) Q3 2022 Earnings Call Transcript

HAUPPAUGE, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2022.

Chembio Diagnostics Reports Third Quarter 2022 Financial Results

HAUPPAUGE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 3, 2022.

Chembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022

HAUPPAUGE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it was awarded a $3.2 million contract from the Centers for Disease Control and Prevention (CDC) for the development and clinical validation of a rapid point-of-care (POC) diagnostic test for syphilis.

Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay

InMed Pharmaceuticals

PaxMedica Inc

Here's what you need to know about trading penny stocks on September 2nd The post Trending Penny Stocks For Your September Watchlist  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trending Penny Stocks For Your September Watchlist

HAUPPAUGE, N.Y., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it is evaluating the potential to develop a monkeypox rapid point-of-care (POC) test. Chembio is exploring the technical requirements for test development leveraging its multiple technology platforms, DPP, SURE CHECK, and STAT PAK, along with funding partners and the broader market opportunity.

Chembio Diagnostics Evaluates Monkeypox Rapid Point-of-Care Test Development

Chembio Diagnostics, Inc. (NASDAQ:CEMI ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Rick Eberly - President and CEO Larry Steenvoorden - Chief Financial Officer Conference Call Participants Per Ostlund - Craig-Hallum Operator Good afternoon, ladies and gentlemen. And welcome to the Chembio Second Quarter 2022 Earnings Conference Call.

Chembio Diagnostics, Inc.'s (CEMI) CEO Rick Eberly on Q2 2022 Results - Earnings Call Transcript

Aethlon Medical

Applied DNA Sciences

E-Home Household Service Holdings Ltd

NanoViricides

SIGA Technologies

Tonix Pharmaceuticals Hld

10 monkeypox stocks and monkeypox penny stocks to watch The post 10 Top Monkeypox Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Monkeypox Stocks To Watch Right Now

Monkeypox penny stocks to watch this week. The post Best Penny Stocks To Buy Now?

News for Chembio Diagnostics Stock (CEMI)